DiaMedica Appoints Rich Pilnik as Chairman of the Board of Directors

DiaMedica Inc. (TSX VENTURE:DMA), a clinical stage biopharmaceutical company
focused on the treatment of diabetes and its complications, announced today the
appointment of Richard Pilnik as Chairman of the Company's Board of Directors. 


Mr. Pilnik has been a member of DiaMedica's Board of Directors since 2009. He
recently retired as Executive Vice President and President of Quintiles
Commercial Solutions, a global pioneer in pharmaceutical services. Mr. Pilnik
previously spent 25 years at Eli Lilly, where he held several leadership
positions including Group Vice President and Chief Marketing Officer. 


"Rich's vast background in the global biopharmaceutical market, healthcare
services experience, and strategic planning and medical/marketing expertise will
be a great complement in driving DiaMedica's product and corporate development,"
said Rick Pauls, President & CEO. 


Mr. Pilnik will replace Rick Pauls as Chairman. Mr. Pauls will continue as
President & CEO and a member of the Board of Directors. 


"I am very pleased to accept the Chairmanship of the Board of DiaMedica and I
look forward to helping the Company advance the development of new and
innovative therapies and cultivating strategic relationships," said Mr. Pilnik. 


Mr. Pilnik has served on the board of directors of Elan Corporation, a
successful bio-pharmaceutical company focused on neurodegenerative diseases,
prior to the company being acquired in 2013. He holds a Bachelor of Arts in
Economics from Duke University and an MBA from the Kellogg School of Management
at Northwestern University.


About DiaMedica

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage
biopharmaceutical company focused on the discovery and development of novel
therapies to treat diabetes and the complications associated with diabetes.
DiaMedica's lead clinical stage product, DM199, is a recombinant human protein
known as rhKLK1 that represents a novel approach to treating diabetes and
associated complications. DiaMedica is also developing a novel monoclonal
antibody, DM204 for the treatment of Type 2 diabetes, which is in preclinical
development.


The Company is listed on the TSX Venture Exchange in Canada under the trading
symbol 'DMA'.


FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, including the intended use of the net proceeds of the Offering,
should be considered forward-looking statements. Such statements are based on
management's exercise of business judgment as well as assumptions made by and
information currently available to management. When used in this document, the
words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and
words of similar import, are intended to identify any forward-looking
statements. You should not place undue reliance on these forward-looking
statements. These statements reflect a current view of future events and are
subject to certain risks and uncertainties as contained in DiaMedica's filings
with Canadian securities regulatory authorities. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results could differ materially from those anticipated in
these forward-looking statements. DiaMedica undertakes no obligation, and does
not intend, to update, revise or otherwise publicly release any revisions to
these forward-looking statements to reflect events or circumstances after the
date hereof, or to reflect the occurrence of any unanticipated events, unless
required by law. Although management believes that expectations are based on
reasonable assumptions, no assurance can be given that these expectations will
materialize.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of the contents of this press
release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica Inc.
John Savage
Chief Financial Officer
763-270-0603
[e-mail]